Search Results (7)
Click the Why column to see why an item matched the search.
Match | Type | Why |
---|
Gaedigk, Andrea | Person |
Why?
|
PharmVar GeneFocus: CYP2C9. | Academic Article |
Why?
|
Cytochrome P-450 CYP2C9 | Concept |
Why?
|
Cytochrome P-450 CYP2C9 Inducers | Concept |
Why?
|
Cytochrome P-450 CYP2C9 Inhibitors | Concept |
Why?
|
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. | Academic Article |
Why?
|
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. | Academic Article |
Why?
|
CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. | Academic Article |
Why?
|
Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. | Academic Article |
Why?
|
Efficiency of CYP2C9 genetic test representation for automated pharmacogenetic decision support. | Academic Article |
Why?
|
Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. | Academic Article |
Why?
|
Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. | Academic Article |
Why?
|
VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. | Academic Article |
Why?
|
Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX: A GeT-RM Collaborative Project. | Academic Article |
Why?
|
CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project. | Academic Article |
Why?
|